ストックスクリーナーアプリを入手
0.258
3.53%
0.0088
前日終値:
$0.2492
開ける：
$0.259
24時間の取引高:
1.59M
Relative Volume:
0.80
時価総額：
$10.59M
収益：
$1.04M
当期純損益:
$-67.50M
株価収益率:
-0.1342
EPS:
-1.9222
ネットキャッシュフロー:
$-60.67M
1週間 パフォーマンス:
+3.66%
1か月 パフォーマンス:
-51.78%
6か月 パフォーマンス:
-60.92%
1年 パフォーマンス:
-89.38%
1日の値動き範囲:
$0.2471
$0.2639
1週間の範囲:
$0.2255
$0.2639
52週間の値動き範囲:
$0.198
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
名前
Vistagen Therapeutics Inc
セクター
電話
650-577-3600
住所
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.258 | 10.59M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2025-12-17 | ダウングレード | Stifel | Buy → Hold |
| 2025-12-17 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-07 | アップグレード | Maxim Group | Hold → Buy |
| 2022-07-22 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 開始されました | Robert W. Baird | Outperform |
| 2021-02-18 | 開始されました | Jefferies | Buy |
| 2021-01-04 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2018-02-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-03-28 | 開始されました | Maxim Group | Buy |
すべてを表示
Vistagen Therapeutics Inc (VTGN) 最新ニュース
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Penny stock Vistagen keeps regulatory plans alive despite anxiety study miss - MSN
Enterprise value to revenue forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN - TradingView
VTGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Price to sales forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN - TradingView
Vistagen (VTGN) Chief Legal Officer adds 36,818 ESPP shares in Form 4 filing - Stock Titan
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Vistagen (VTGN) CEO adds 36,818 ESPP shares, now holds over 54,000 directly - Stock Titan
ESPP grant gives Vistagen (NASDAQ: VTGN) CFO 11,712 new shares - Stock Titan
$VistaGen Therapeutics (VTGN.US)$ - Moomoo
VistaGen pivots fasedienol toward long-term anxiety treatment - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Ther - The National Law Review
Vistagen’s anxiety disorder drug misses main goal in late-stage trial, shares plummet - Classic Rock 103.5 WIMZ
symbol__ Stock Quote Price and Forecast - CNN
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder. - Bitget
Vistagen fails another phase 3 anxiety trial, spies path forward - Fierce Biotech
Vistagen (VTGN) Reports Phase 3 Trial Results for Fasedienol - GuruFocus
VTGN: Post-hoc analyses show fasedienol benefits very severe social anxiety, guiding a new LSAS-based trial - TradingView
Vistagen reports PALISADE-4 miss on primary endpoints; positive post-hoc signal in very severe SAD subgroup - TradingView
Vistagen (NASDAQ: VTGN) Phase 3 fasedienol trial misses main goal but shows severe-SAD signal - Stock Titan
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Business Wire
Vistagen Therapeutics, Inc. Actuals & Estimates (NASDAQ:VTGN) - TradingView
Vistagen Therapeutics, Inc. Actuals & Estimates (BMV:VTGN) - TradingView
Vistagen Therapeutics, Inc. Actuals & Estimates (BOATS:VTGN) - TradingView
VTGN Forecast — Price Target — Prediction for 2027 - TradingView
Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth - The Globe and Mail
Vistagen Therapeutics directors to step down after 2026 annual meeting - Investing.com UK
Vistagen Therapeutics directors to step down after 2026 annual meeting By Investing.com - Investing.com India
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vistagen Therapeutics Inc (VTGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting - Stock Titan
Vistagen Therapeutics Inc (VTGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vistagen Therapeutics Inc (VTGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vistagen Therapeutics Inc (VTGN) Institutional Confidence - TradingKey
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - BioSpace
VistaGen Therapeutics (VTGN) Q4 2026 earnings summary - Quartr
VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative
vtgn-20260331 - SEC.gov
VTGN: Net loss increased to $69.7M as R&D spending rose, with cash reserves at $45.4M and going concern risk - TradingView
Vistagen (VTGN) outlines Phase 3 fasedienol data and broad intranasal CNS pipeline - Stock Titan
Vistagen Reports FY2026 Net Loss $69.7M; Cash and Marketable Securities $45.4M - TradingView
VTGN: Advanced clinical milestones and maintained cash runway despite increased net loss - TradingView
Vistagen (NASDAQ: VTGN) advances fasedienol trials as FY 2026 loss deepens - Stock Titan
Press Release: Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Moomoo
Generalized Anxiety Disorder Market: Growth Momentum Across 7MM to 2036 – DelveInsight | VistaGen Therapeutics, Fabre-Kramer Pharm, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Lab - Barchart.com
Vistagen Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
VTGN Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Edges HigherGuidance vs Actual - newsline.com
Vistagen Therapeutics Inc (VTGN) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):